Literature DB >> 12197895

Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

E A Waterman1, E H Kemp, D J Gawkrodger, P F Watson, A P Weetman.   

Abstract

Recent studies have demonstrated the presence of circulating MelanA (MART1)-specific cytotoxic T lymphocytes in a significant number of vitiligo patients when compared to control subjects. High levels of the skin-homing receptor cutaneous lymphocyte-associated antigen were expressed on the T cells and their frequency correlated with the extent of depigmentation and disease activity in the vitiligo patients. The present study was designed to examine vitiligo patient sera for the presence of autoantibodies to MelanA. The incidence of autoantibodies to MelanA in patients with vitiligo (n = 51) and in healthy individuals (n = 20) was examined using a radiobinding assay with 35S]-labelled MelanA and using Western blot analysis with a glutathione S-transferase (GST)-MelanA fusion protein. Autoantibodies to MelanA could not be detected in any of the vitiligo patient sera or control sera analysed using either of these detection systems. It is therefore possible that MelanA only induces cellular rather than humoral autoreactivity in vitiligo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197895      PMCID: PMC1906462          DOI: 10.1046/j.1365-2249.2002.01949.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1997-09       Impact factor: 4.330

2.  Melanoma-associated hypopigmentation: where are the antibodies?

Authors:  O Merimsky; Y Shoenfeld; E Baharav; M Altomonte; S Chaitchik; M Maio; S Ferrone; P Fishman
Journal:  Am J Clin Oncol       Date:  1996-12       Impact factor: 2.339

3.  Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay.

Authors:  E H Kemp; D J Gawkrodger; S MacNeil; P F Watson; A P Weetman
Journal:  J Invest Dermatol       Date:  1997-07       Impact factor: 8.551

4.  Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Br J Dermatol       Date:  1998-11       Impact factor: 9.302

5.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors:  S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

6.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Authors:  F O Nestle; S Alijagic; M Gilliet; Y Sun; S Grabbe; R Dummer; G Burg; D Schadendorf
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

7.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

8.  Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.

Authors:  T Okamoto; R F Irie; S Fujii; S K Huang; A J Nizze; D L Morton; D S Hoon
Journal:  J Invest Dermatol       Date:  1998-12       Impact factor: 8.551

9.  A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.

Authors:  E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

10.  High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.

Authors:  G S Ogg; P Rod Dunbar; P Romero; J L Chen; V Cerundolo
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  2 in total

1.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

Review 2.  Engineered antigen-specific regulatory T cells for autoimmune skin conditions.

Authors:  Zhussipbek Mukhatayev; Yekaterina O Ostapchuk; Deyu Fang; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2021-01-18       Impact factor: 17.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.